NCAM1 and neoplasm: Investigation into the possible explanations for the better cytolytic activities against tumor cells demonstrated for the CD3+ CD56+ cells over their CD3+ CD56− counterpart, originally revealed that the CD3+ CD56+ cells consist of a higher proportion of CD8+ cells, as well as a more differentiated effector phenotype as well as a higher content of granzyme [5].